Welcome to SoliPharma

SoliPharma is a specialty pharmaceutical company with pharmaceutical innovation center based in Hangzhou, China and business development/product registration office in U.S.
SoliPharma’s mission is to Bring Challenging Molecules to Global Markets faster and better through SoliTech® Solutions. We focus on providing comprehensive solutions to our clients worldwide from drug substance (salt/polymorph screening, crystallization), to drug product (formulation/analytical) development, until obtaining the final approval of market authorization (FDA GMP/regulatory affair).

About Us

With our track record in China/U.S./Canada/European product innovation and business relationship, SoliPharma strives for delivering both innovative products (505(b)2 with modified release/new combinations) and difficult generic products (NTI, highly variable, IP hurdles etc). Leveraging global partnership with API suppliers, contract manufacturing and product distribution, SoliPharma is devoted to bringing medical products faster to meet patients’ urgent and unmet medical needs.

SoliTech® Solutions

  • Organ Transplant
  • Blood Cell Disorders
  • Urological Disease

Bring Challenging Molecules to the Global Markets

SoliPharma is a specialty pharmaceutical company. We provide technical solutions to both innovative and difficult generic products for global markets.

Excellence in Drug R&D since 2010

SoliPharma is an innovation driven company based in Hangzhou, China and Boston, U.S.

500+ Compounds

SoliPharma’s mission is to Bring Challenging Molecules to Global Markets faster and better through SoliTech® Solutions.

10000+ Testings per year

SoliPharma focuses on providing comprehensive solutions for pharmaceutical development and product registration.

500+ Customers

SoliPharma collaborates with pharmaceutical companies in Asia, North America and Europe.

5+ Strategic Global Partners

Strategic partnership with industry leaders for development, supply and distribution to global markets.

image-box
领业零缺陷通过美国cGMP检查

2018年8月27日至29日,美国FDA检查官在对领业医药质量管理体系现场核查总结会上,直接宣布并祝贺领业医药以483零缺陷通过...

image-box
领业董事长出席胃癌国际论坛

2017年11月17日到19日,第十七届全军普通外科专业委员会学术会议暨第三届长征胃癌国际论坛于上海隆重召开。

image-box
领业成功实现片剂开发

技术服务类型:临床前处方及制剂研究,制剂工艺开发及产业化,仿制药固体制剂质量一致性评价

image-box
领业医药首轮融资签约仪式

2015年9月10日上午10点, 在杭州高科技企业孵化器多功能厅隆重举行“领业医药首轮融资签约仪式”。